Edwards Lifesciences
30-Second Executive Brief
Executive Assessment
Edwards Lifesciences functions as an established institution within Healthcare & Life Sciences, backed by 47% sourcing coverage, with a stable competitive position.
- Maintains 3 mapped relationships across the graph
- 47% sourcing coverage across sourced relationships
- Tracked as established institution within the Healthcare & Life Sciences category
Executive Snapshot
- Strategic Role
- Established Institution
- Sourcing Coverage
- 47%
- Ecosystem Influence
- High
- Strategic Momentum
- Steady
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 3
- Technology Domains
- 5
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
The structural heart company that pioneered transcatheter aortic valve replacement (TAVR), raising its full-year 2026 sales growth guidance to 10-11% after Q2 2026 TAVR sales grew 10.5% to $1.3 billion (Q1 2026 TAVR sales grew 14.4% to $1.2 billion). Edwards is guiding to $4.75-5.0 billion in full-year TAVR sales, buoyed by long-term PARTNER 3/PARTNER 2 trial data and the practice-changing EARLY TAVR trial, with an updated US TAVR National Coverage Determination and new European aortic-stenosis treatment guidelines expected by Q4 2026.
Leading Indicators
Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Federal contract disclosures
Department of Veterans Affairs — $476,000: PROSTHETICS - SURGICAL IMPLANT TAVR X14
USAspending.gov · Jul 22, 2026
Department of Veterans Affairs — $402,000: HEMODYNAMIC MONITORING SYSTEM
USAspending.gov · Apr 15, 2026
Department of Veterans Affairs — $374,000: SAPIEN 3 RESILIA HEART VALVE
USAspending.gov · Jun 1, 2026
Department of Veterans Affairs — $306,000: EXPRESS REPORT: TAVR HEART VALVES
USAspending.gov · Jan 1, 2026
Department of Veterans Affairs — $266,000: EXPRESS REPORT: STL HEART VALVES
USAspending.gov · Oct 1, 2025
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
1 source
- Medical Device Network — Edwards lifts FY26 growth outlook following steady Q2 performancenews
Latest Activity
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Sep 7, 2026
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding Edwards Lifesciences — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Market Intelligence
UnverifiedCredibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.
Edwards' TAVR concentration is a strength today but a single point of failure against the pending NCD update
30% confidenceEdwards raised full-year 2026 sales growth guidance to 10-11% on strong TAVR momentum, with the entire structural heart franchise now awaiting an updated US TAVR National Coverage Determination and new European treatment guidelines expected by Q4 2026.
This is InsightNodes' own interpretive read: Edwards' near-total reliance on TAVR for growth has been a clear asset while trial data (PARTNER, EARLY TAVR) and guidelines have moved in its favor, but that same concentration means the pending NCD update is a binary-feeling catalyst for the whole company rather than one input among many -- a less TAVR-concentrated peer would feel a reimbursement setback less acutely, which is likely why Boston Scientific's MiRus investment reads as an attempt to chip away at a segment where the leader currently has outsized exposure to a single regulatory decision.
InsightNodes analysis of Edwards Lifesciences' TAVR concentration · Aug 14, 2026
Edwards Lifesciences's Timeline
A sourced, dated history of Edwards Lifesciences's key moments — founding to present.
Apr 2026 · Q1 2026: TAVR sales up 14.4%
Edwards reported Q1 2026 TAVR sales of $1.2 billion, up 14.4% year-over-year, supported by long-term PARTNER trial data and the EARLY TAVR trial.
Jul 2026 · Q2 2026: raises full-year guidance
Edwards reported Q2 2026 TAVR sales growth of 10.5% to $1.3 billion and raised full-year 2026 sales growth guidance to 10-11%.